` MDNA (Medicenna Therapeutics Corp) vs S&P TSX Composite Index (Canada) Comparison - Alpha Spread

MDNA
vs
S
S&P TSX Composite Index (Canada)

Over the past 12 months, MDNA has underperformed S&P TSX Composite Index (Canada), delivering a return of -45% compared to the S&P TSX Composite Index (Canada)'s +28% growth.

Stocks Performance
MDNA vs S&P TSX Composite Index (Canada)

Loading
MDNA
S&P TSX Composite Index (Canada)
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
MDNA vs S&P TSX Composite Index (Canada)

Performance Gap Between MDNA and GSPTSE
HIDDEN
Show

Performance By Year
MDNA vs S&P TSX Composite Index (Canada)

Loading
MDNA
S&P TSX Composite Index (Canada)
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Medicenna Therapeutics Corp vs Peers

S&P TSX Composite Index (Canada)
MDNA
ABBV
AMGN
GILD
VRTX
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Medicenna Therapeutics Corp
Glance View

Market Cap
84.2m CAD
Industry
Biotechnology

Medicenna Therapeutics Corp. is a clinical stage immuno-oncology company. The company is headquartered in Toronto, Ontario and currently employs 13 full-time employees. The company went IPO on 2015-07-13. The firm is primarily engaged in the development and commercialization of interleukin-2 (IL-2), interleukin-4 (IL-4) and interleukin-13 (IL-13) Superkines and Empowered Superkines for the treatment of cancer, inflammation and immune-mediated diseases. Its Bi-functional SuperKine ImmunoTherapies (BiSKITs) platform is designed to enable the ability of Superkines to treat immunologically cold tumors. The Company’s product candidate MDNA55, is an Empowered Superkine developed as a therapeutic for recurrent glioblastoma multiforme (rGBM), a fatal form of brain cancer. MDNA11, an IL-2 Superkine that has been fused with human recombinant albumin. The firm has not earned any revenues from its products.

MDNA Intrinsic Value
Not Available
Back to Top